Iveric Bio Inc (NASDAQ:ISEE) Short Interest Increased By 3.09%

The stock of Iveric Bio Inc (NASDAQ:ISEE) registered an increase of 3.09% in short interest. ISEE’s total short interest was 557,900 shares in September as published by FINRA. Its up 3.09% from 541,200 shares, reported previously. With 154,800 shares average volume, it will take short sellers 4 days to cover their ISEE’s short positions. The short interest to Iveric Bio Inc’s float is 1.73%.

The stock increased 0.85% or $0.01 during the last trading session, reaching $1.18. About 146,416 shares traded or 76.86% up from the average. IVERIC bio, Inc. (NASDAQ:ISEE) has declined 50.83% since September 13, 2018 and is downtrending. It has underperformed by 50.83% the S&P500.

IVERIC bio, Inc., a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases with a focus on age-related and orphan retinal diseases. The company has market cap of $49.04 million. The firm is developing Zimura, an inhibitor of complement factor C5, which is in Phase IIb clinical trials for the treatment of geographic atrophy , a late-stage form of dry age-related macular degeneration (AMD) characterized by retinal cell death and degeneration of tissue in the central portion of the retina known as the macula; and autosomal recessive Stargardt disease (STGD1), which is an orphan inherited retinal disease (IRD). It has a 0.75 P/E ratio. It is also developing High temperature requirement A serine peptidase 1 protein (HtrA1) inhibitors for the treatment of GA secondary to dry AMD and other age-related retinal diseases, such as wet AMD and idiopathic polypoidal choroidal vasculopathy.

More notable recent IVERIC bio, Inc. (NASDAQ:ISEE) news were published by: Seekingalpha.com which released: “Ophthotech Corporation 2018 Q3 – Results – Earnings Call Slides – Seeking Alpha” on October 31, 2018, also Businesswire.com with their article: “IVERIC bio Reports First Quarter 2019 Financial and Operating Results – Business Wire” published on May 08, 2019, Businesswire.com published: “IVERIC bio Announces Successful Advancement of LCA10 Minigene Program and Expansion of Orphan Gene Therapy Portfolio with USH2A-Related Inherited Retinal Diseases Program – Business Wire” on July 23, 2019. More interesting news about IVERIC bio, Inc. (NASDAQ:ISEE) were released by: Seekingalpha.com and their article: “Ophthotech changes name to IVERIC bio; shares up 7% premarket – Seeking Alpha” published on April 16, 2019 as well as Businesswire.com‘s news article titled: “IVERIC bio Reports Second Quarter 2019 Financial and Operating Results – Business Wire” with publication date: August 01, 2019.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.